GMP Certification awarded to China Biologic Products, Inc for its New Coagulation Factor Facility

GMP certification has been awarded to the majority owned subsidiary of China Biologic Products, Inc from CFDA (China Food and Drug Administration).The subsidiary is known as Shandong Taibang Biological Products Co. Ltd and has been awarded the GMP certification for its new coagulation factor production facility. This facility was inspected by CFDA in June 2014.

China Biologic is located in Beijing, China and is a leading plasma based pharmaceutical company in China and its products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. Its majority owned subsidiary Shandong Taibang Biological Products Co. Ltd is the manufacturer of over 20 different dosages of plasma-based products.

The new facility which has been given GMP certification will be responsible for the production of plasma-derived prothrombin complex concentrate, factor VIII and various other coagulation factors in the pipeline. This new facility is capable of producing multiple coagulation factors parallely on a larger scale compared to the existing production facilities of the company.

According to the CEO of the China Biologic Mr. David (Xiaoying) Gao, “The new facility once operational will increase the overall production capacity and enable to continue to meet the growing demand for plasma-based products in China”. He also said that the new facility will have a positive impact on the 2015 financial results.